This sample transcript is from a panel discussion held after the 2007 APA meeting. The research objectives of the panel were to review information presented at the conference and discuss up-to-date treatment practices for adult attention deficit hyperactivity disorder (ADHD).
Specifically, MedPanel researchers wanted to understand psychiatrists' opinions on:
A) Pharmacotherapeutic options including:
Atomoxetine (Eli Lilly’s Strattera)
B) Specific considerations in the prescription of each of the above drugs including dosing and side effects
C) Potential pharmacotherapeutic options including:
D) The incidence of co-morbidities associated with ADHD including bipolar disorder and substance
E) Desvenlafaxine, a new serotonin-norepinephrine reuptake inhibitor (SNRI)